NCT02220673View on ClinicalTrials.gov

Serial Lung Function Measurements in Healthy and Mild Asthmatic Adults After Oral Inhalation of Ethanolic Solutions Containing Two Concentrations of the Excipient Butylated Hydroxytoluene (BHT) Administered With the Respimat® B (RMT-B)

PHASE1CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

May 31, 2010

Conditions
Asthma
Interventions
DRUG

BHT 0.1%

DRUG

BHT 0.5%

DRUG

Placebo for RMT-B

DRUG

Placebo for HFA-MDI

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY